Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT ID: NCT00016302
Last Updated: 2013-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2001-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00408005
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00103285
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00558519
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00109837
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00003700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Determine the feasibility of the addition of nelarabine to modified multiagent Berlin-Frankfurt-Muenster-86 chemotherapy in patients with newly diagnosed T-cell acute lymphoblastic leukemia.
SECONDARY OBJECTIVES:
I. Determine the pharmacokinetics and intracellular pharmacology of nelarabine in these patients.
OUTLINE: This is a pilot, multicenter study.
Prednisone Response Pre-Induction: All patients receive oral prednisone three times daily on days -7 to -1 and methotrexate intrathecally (IT) on day -7\* of week 0. Good prednisone responders proceed to induction on regimen A. Poor prednisone responders proceed to induction on regimen C.
NOTE: \*Patients who have received cytarabine IT within the week prior to study entry receive methotrexate IT on day -6.
Regimen A (good prednisone responders) (closed as of 2/27/03):
Induction (weeks 1-5): Patients receive vincristine IV on days 1, 8, and 15; oral prednisone three times daily on days 1-14; daunorubicin IV over 15 minutes on days 1, 8, 15, and 22; asparaginase intramuscularly (IM) on days 12, 15, 18, 22, 24, 27, 30, and 33; and methotrexate IT on day 1.
If bone marrow is M1, week 6 of induction therapy begins on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues. Those patients with minimal residual disease (MRD) on day 36 proceed to regimen B.
Induction (weeks 6-9): Patients receive cyclophosphamide IV over 1 hour on days 36 and 63; cytarabine IV over 72 hours on days 38-40, 45-47, 52-54, and 59-61; oral mercaptopurine daily on days 36-63; and methotrexate IT on days 45 and 59.
Consolidation (weeks 10-19): Patients receive oral mercaptopurine on days 64-119; methotrexate IV over 24 hours and leucovorin calcium IV, or orally as tolerated, on days 71, 85, 99, and 113; and methotrexate IT on days 71, 85, 99, and 113. (Patients begin methotrexate once blood counts recover and only if bone marrow is M1).
Reinduction (weeks 20-29): Patients receive oral dexamethasone three times daily on days 134-154; vincristine IV on days 141 and 148; doxorubicin IV over 15 minutes on days 134, 141, 148, and 155; and asparaginase IM on days 141, 144, 148, 151, 154, and 157. Beginning on day 169 or when blood counts recover, patients receive cyclophosphamide IV on day 169, cytarabine IV over 72 hours on days 171-173 and 178-180; oral thioguanine daily on days 169-182; and methotrexate IT on days 171 and 178. Patients also receive cranial irradiation for up to 10 days beginning on day 189.
Maintenance (weeks 30-101): Patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 9 courses.
Regimen B (patients with MRD on day 36 of regimen A) (closed as of 2/27/03):
Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.
Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.
Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.
Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses.
Regimen C (poor prednisone responders from stage 1 of study and all patients entered during stage 2 of study) (closed as of 2/27/03):
Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.
If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.
Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.
Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.
Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.
Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B.
Regimen D (effective 5/2004):
Induction (weeks 1-5): Patients receive vincristine IV on days 1, 8, and 15; oral prednisone 3 times a day on days 1-14; daunorubicin IV over 15 minutes on days 1, 8, 15, and 22; nelarabine IV over 1 hour on days 29-33; asparaginase IM on days 12, 15, 18, 22, 24, 27, 30, and 33; and methotrexate IT on day 1.
If bone marrow is M1, week 6 of induction therapy begins on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.
Induction (weeks 6-9): Patients receive cyclophosphamide IV over 1 hour on days 36 and 50; cytarabine IV or SC on days 36-39, 43-46, 50-53, and 57-60; oral mercaptopurine once daily on days 36-63; and methotrexate IT on days 43 and 57.
Patients who are poor responders to prednisone in induction therapy proceed to regimen F. Patients who are good responders to prednisone but have MRD after induction therapy proceed to regimen E. Patients who are good responders to prednisone and have no MRD after induction therapy continue therapy on regimen D.
Consolidation (weeks 10-19): Patients must have M1 marrow to proceed. Patients receive oral mercaptopurine on days 70-126; methotrexate IV over 24 hours on days 77, 84, 91, and 98; leucovorin calcium IV or orally every 6 hours on days 78-79, 85-86, 92-93, and 99-100; and methotrexate IT on days 77, 84, 91, and 98.
Reinduction (weeks 20-29): Patients \< 13 years old receive dexamethasone 3 times daily on days 140-161. Patients ≥ 13 years old receive oral dexamethasone on days 140-146 and 155-161; nelarabine IV on days 169-173; vincristine IV over 15 minutes on days 140, 147, and 153; pegaspargase IM on day 143; cyclophosphamide IV on day 176; cytarabine IV or SC on days 176-179 and 183-186; oral thioguanine on days 176-189; and methotrexate IT on days 176 and 183. Patients with CNS disease undergo craniocervical radiotherapy beginning on day 196 and continuing for 7-10 days.
Maintenance (weeks 30-61): Patients receive oral mercaptopurine on days 1-28 and 36-56; oral methotrexate on days 1, 8, 15, 22, 36, 43, and 50; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses.
Maintenance (weeks 62-101): Patients receive vincristine IV on day 1; oral dexamethasone twice daily on days 1-5; oral mercaptopurine on days 1-56; and oral methotrexate on days 1, 8, 15, 22, 29, 36, 43, and 50. Treatment repeats every 8 weeks for 5 courses.
Regimen E (good responders to induction prednisone but with MRD) (effective 5/2004): Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
Regimen F (poor responders to induction prednisone) (effective 5/2004): Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
Patients are followed monthly for 1 year, every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 100 patients (30 for regimens A, B, and C; 70 for regimens D, E, and F) will be accrued for this study within 9-29 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Regimen A
See detailed description.
prednisone
Given orally
vincristine sulfate
Given IV
daunorubicin hydrochloride
Given IV
asparaginase
Given IM
methotrexate
Given IT and orally
cyclophosphamide
Given IV
cytarabine
Given IV or SC
mercaptopurine
Given orally
leucovorin calcium
Given IV or orally
dexamethasone
Given orally
doxorubicin hydrochloride
Given IV
thioguanine
Given orally
radiation therapy
Undergo cranial irradiation
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
Regimen B
Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.
Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.
Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.
Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses.
prednisone
Given orally
vincristine sulfate
Given IV
daunorubicin hydrochloride
Given IV
asparaginase
Given IM
methotrexate
Given IT and orally
cyclophosphamide
Given IV
cytarabine
Given IV or SC
mercaptopurine
Given orally
leucovorin calcium
Given IV or orally
dexamethasone
Given orally
doxorubicin hydrochloride
Given IV
thioguanine
Given orally
radiation therapy
Undergo cranial irradiation
nelarabine
Given IV
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
Regimen C
Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.
If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.
Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.
Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.
Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.
Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B.
prednisone
Given orally
vincristine sulfate
Given IV
daunorubicin hydrochloride
Given IV
asparaginase
Given IM
methotrexate
Given IT and orally
cyclophosphamide
Given IV
cytarabine
Given IV or SC
mercaptopurine
Given orally
leucovorin calcium
Given IV or orally
dexamethasone
Given orally
doxorubicin hydrochloride
Given IV
thioguanine
Given orally
radiation therapy
Undergo cranial irradiation
nelarabine
Given IV
radiation therapy
Undergo craniocervical radiotherapy
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
Regimen D
See detailed description.
prednisone
Given orally
vincristine sulfate
Given IV
daunorubicin hydrochloride
Given IV
asparaginase
Given IM
methotrexate
Given IT and orally
cyclophosphamide
Given IV
cytarabine
Given IV or SC
mercaptopurine
Given orally
leucovorin calcium
Given IV or orally
dexamethasone
Given orally
thioguanine
Given orally
nelarabine
Given IV
pegaspargase
Given IM
radiation therapy
Undergo craniocervical radiotherapy
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
Regimen E
Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
prednisone
Given orally
vincristine sulfate
Given IV
daunorubicin hydrochloride
Given IV
asparaginase
Given IM
methotrexate
Given IT and orally
cyclophosphamide
Given IV
cytarabine
Given IV or SC
mercaptopurine
Given orally
leucovorin calcium
Given IV or orally
dexamethasone
Given orally
thioguanine
Given orally
nelarabine
Given IV
pegaspargase
Given IM
radiation therapy
Undergo craniocervical radiotherapy
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
Regimen F
Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
prednisone
Given orally
vincristine sulfate
Given IV
daunorubicin hydrochloride
Given IV
asparaginase
Given IM
methotrexate
Given IT and orally
cyclophosphamide
Given IV
cytarabine
Given IV or SC
mercaptopurine
Given orally
leucovorin calcium
Given IV or orally
dexamethasone
Given orally
thioguanine
Given orally
nelarabine
Given IV
pegaspargase
Given IM
radiation therapy
Undergo craniocervical radiotherapy
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prednisone
Given orally
vincristine sulfate
Given IV
daunorubicin hydrochloride
Given IV
asparaginase
Given IM
methotrexate
Given IT and orally
cyclophosphamide
Given IV
cytarabine
Given IV or SC
mercaptopurine
Given orally
leucovorin calcium
Given IV or orally
dexamethasone
Given orally
doxorubicin hydrochloride
Given IV
thioguanine
Given orally
radiation therapy
Undergo cranial irradiation
nelarabine
Given IV
pegaspargase
Given IM
radiation therapy
Undergo craniocervical radiotherapy
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High-risk disease, defined as meeting at least 1 of the following criteria:
* WBC at least 50,000/mm\^3
* Age 10 years or over
* Patients with WBC at least 25,000/mm\^3 AND at least 50% peripheral blood blasts are eligible provided bone marrow aspiration was contraindicated (e.g., patient was not eligible for anesthesia or sedation due to respiratory distress secondary to anterior mediastinal mass)
* Concurrent registration to POG 9900 within the past 8 days required
* Performance status - Karnofsky 50-100% (over 10 years of age)
* Performance status - Lansky 50-100% (10 years of age and under)
* See Disease Characteristics
* Bilirubin no greater than 1.5 mg/dL
* SGPT less than 5 times normal
* Creatinine normal
* Creatinine clearance or glomerular filtration rate at least 60 mL/min
* No pre-existing neuropathy of grade 2 or worse unless due to leukemic infiltration
* Not pregnant or nursing
* Fertile patients must use effective contraception
* No prior biologic therapy
* No more than 72 hours since prior intrathecal cytarabine
* No other prior chemotherapy
* Prior steroids allowed
* No chronic steroid treatment for another disease
* Prior emergency radiotherapy to mediastinum for severe respiratory distress allowed
1 Year
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kimberly Dunsmore
Role: PRINCIPAL_INVESTIGATOR
Children's Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Oncology Group
Arcadia, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AALL00P2
Identifier Type: -
Identifier Source: secondary_id
CDR0000068620
Identifier Type: REGISTRY
Identifier Source: secondary_id
NCI-2012-01857
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.